For the first time, scientists have shown that concentrations of vitamin C in the blood of older adults are directly associated with the physical integrity of the brain’s default mode network—a system central to memory and executive function. The observational study of 2,044 people, with an average age of 69, used blood tests rather than dietary questionnaires and found that those with higher vitamin C had larger grey matter volumes and stronger structural connectivity within this network. The finding, published in PLOS ONE, arrives just months after two large phase‑3 trials of oral semaglutide—Evoke and Evoke+—failed to demonstrate any slowing of cognitive decline in early Alzheimer’s disease, disappointing researchers who had hoped the diabetes and obesity drug might protect the brain.

Neuroscientists in Paris and Tokyo note that the default mode network is among the regions most vulnerable in Alzheimer’s and depression. Vitamin C’s antioxidant properties may reduce the oxidative stress that contributes to neurodegeneration. The concept of “cognitive reserve” helps explain why some individuals withstand such damage better: neurologists observe that patients with higher levels of education or lifelong intellectual engagement can have comparable brain lesions yet delay clinical symptoms by as much as eight years. Activities that challenge the brain—learning a language, playing a musical instrument, solving sudoku—are thought to build this reserve by strengthening neural connections well into old age. The Alzheimer’s Association has emphasized that early symptoms, such as forgetting recently learned information or struggling to plan familiar tasks, can appear subtly and are often mistaken for normal ageing.

While the vitamin C data are observational and cannot prove causation, they add weight to public‑health advice promoting diets rich in fruit and vegetables. The more established notion of cognitive reserve also underscores a stark inequality: socioeconomic and educational differences determine how well a brain can compensate for pathology. At the same time, uncontrolled financial stress can consume mental bandwidth, impairing decision‑making and potentially accelerating cognitive wear. Analysts in London and São Paulo note that despite the Evoke setbacks, interest is shifting towards whether GLP‑1 drugs might prevent decline if given at the stage of mild cognitive impairment; a retrospective analysis of over 44,000 patients found that tirzepatide was associated with a lower incidence of mild cognitive impairment compared with semaglutide.

The next milestones will come from interventional trials testing vitamin C supplementation and from long‑term studies of GLP‑1 analogues in pre‑clinical populations. For now, the evidence suggests that the most reliable shield for the ageing brain may be built over decades through diet, education, and mental engagement—resources that remain unevenly distributed across societies.